R&D Insights: How Amgen Inc. and Alkermes plc Allocate Funds

R&D Spending: A Tale of Two Biotech Giants

In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Amgen Inc. and Alkermes plc have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, Amgen consistently allocated a significant portion of its resources to R&D, with expenses peaking at nearly $4.8 billion in 2021. This represents a steady increase of approximately 12% from 2014. In contrast, Alkermes' R&D spending has been more volatile, with a notable spike in 2022, reaching over $393 million, a dramatic increase from its 2014 expenditure. This fluctuation highlights Alkermes' strategic shifts in response to market demands and opportunities. As these companies navigate the evolving biotech landscape, their R&D investments will continue to shape their competitive edge and innovation potential.